China Medical GatewayLoading your healthcare gateway…

Prostate Cancer in China

Overview

Prostate cancer is the most common male cancer and usually slow-growing. Modern risk stratification matches each patient to the right option — from active surveillance for low-risk disease to robotic surgery or precision radiotherapy for aggressive tumors.

Chinese urology centers run high-volume robotic prostatectomy programs with nerve-sparing techniques that preserve urinary control and erectile function.

Symptoms & Signs

Urinary frequency, weak stream and nocturia — usually from coexisting benign enlargement rather than the cancer itself

Early cancer is typically silent and detected by PSA blood testing

Blood in urine or semen in locally advanced disease

Bone pain, particularly in the lower back and hips, when disease has spread

Unexplained weight loss and fatigue in advanced stages

Many screen-detected cancers would never cause symptoms if left untreated, hence the surveillance option

Diagnosis

PSA blood testing, often with free-to-total PSA ratio

Multiparametric MRI (mpMRI) of the prostate identifying suspicious lesions

MRI-ultrasound fusion targeted biopsy of suspicious areas

PSMA PET-CT for precise staging of intermediate and high-risk disease

Gleason/ISUP grading from biopsy determining aggressiveness

Genomic testing of biopsy tissue refining risk estimates

Treatment Options

Active surveillance with regular PSA, MRI and biopsy for low-risk disease

Robotic radical prostatectomy with nerve-sparing technique for localized intermediate and high-risk cancer

External-beam radiotherapy (IMRT) with or without brachytherapy boost

SBRT delivering curative doses in five sessions

Androgen-deprivation therapy with novel hormonal agents for advanced disease

Chemotherapy and targeted radiotherapy (e.g. radium-class) for metastatic stages

Advanced Technologies & Novel Drug

da Vinci robotic surgery with intraoperative nerve monitoring

Fusion biopsy platforms fusing MRI targets with live ultrasound

PSMA PET molecular imaging redefining staging accuracy

LDR brachytherapy and focal-therapy options for selected tumors

Novel androgen-receptor inhibitors and PARP inhibitors for advanced disease

Hospital & Specialist

Return to Home